Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention

Journal of Clinical Pharmacology

Volumn 55, Issue 2, 2015, Pages 123-131

  Wu, Hongjiang ^a   Li, Dongmei ^b   Fang, Minhua ^a   Han, Hongguang ^a   Wang, Huishan ^a  

^a Shenyang Northern Hospital   (China)

^b Chinese Peoples Liberation Army 463 Hospital   (China)

Author keywords

atorvastatin; contrast induced acute kidney injury; coronary angiography; meta analysis; percutaneous coronary intervention

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CONTRAST MEDIUM; CYSTATIN C; CREATININE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ANGIOCARDIOGRAPHY; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; INCIDENCE; LOW DRUG DOSE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SHORT COURSE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE KIDNEY INJURY; AGED; BLOOD; CHEMICALLY INDUCED; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED;

ACUTE KIDNEY INJURY; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921019098     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.411     Document Type: Review

References (42)

1. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32 (23): 2999-3054.
2. McCullough P,. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv. 2006; 67 (3): 335-343.
3. Nash K, Hafeez A, Hou S,. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002; 39 (5): 930-936.
4. Gupta R, Gurm HS, Bhatt DL, Chew DP, Ellis SG,. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv. 2005; 64 (4): 442-448.
5. Roghi A, Savonitto S, Cavallini C, et al. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality. J Cardiovasc Med (Hagerstown). 2008; 9 (4): 375-381.
6. Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008; 52 (8): 599-604.
7. Perrin T, Descombes E, Cook S,. Contrast-induced nephropathy in invasive cardiology. Swiss Med Wkly. 2012; 142: w13608.
8. Zhang T, Shen LH, Hu LH, He B,. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2011; 33 (4): 344-351.
9. Zhou Y, Yuan WJ, Zhu N, Wang L,. Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Clin Nephrol. 2011; 76 (6): 475-483.
10. Takagi H, Umemoto T,. A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy. Int J Cardiol. 2011; 153 (3): 323-325.
11. Zhou X, Jin YZ, Wang Q, Min R, Zhang XY,. Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography. Zhonghua Xin Xue Guan Bing Za Zhi. 2009; 37 (5): 394-396.
12. Hua XP, Wu RX, Yang Y, Cao Z, Chen B,. Prevention of contrast-induced nephropathy using high-dose atorvastatin in patients with coronary heart disease undergoing elective percutaneous coronary intervention. Mil Med J S Chin. 2010; 24 (6): 448-451.
13. Lin J, Hong LR, Qiu Y, Xie YH, Fang YQ, Ke SZ,. Clinical research of atorvastatin on preventing contrast-induced nephropathy in patients underwent coronary artery CTA. Clin Med Eng. 2010; 17 (12): 48-50.
14. Dong GF, Wu SQ, Yao QH, Chen BW, Yang Q, Yang PG,. Effect of high dose atorvastatin in preventing contrast induced nephropathy in elderly patients underwent emergency percutaneous coronary intervention. J Clin Cardiol. 2011; 27 (10): 757-759.
15. Yang J, Ding ZM, Liu F, Luo P, Ding YN,. Efficacy of different dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography. Chin J Gerontol. 2011; 31 (10): 3905-3907.
16. Chen R, Ruan CW, Wang ZC, Li ZS, Shen Y, Yuan L,. Effect of atorvastatin intensive treatment on kidney function in patients with coronary heart disease after percutaneous transluminal coronary intervention therapy. Chin J Clin Pharm. 2011; 20 (2): 82-85.
17. Zeng Z, Lu DF, Zeng SH, Lu DX, He WK,. Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography. Hainan Med J. 2011; 22 (10): 44-46.
18. Cao SP, Wang P, Cui K, Zhang L, Hou YQ,. Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress. J South Med Univ. 2012; 32 (11): 1600-1602.
19. Peng W, Li CY, Wang YD,. Effect of preloading with atorvastatin on contrast-induced nephropathy in patients percutaneous coronary intervention. Chin J Clin. 2012; 6 (16): 4953-4954.
20. Liu X, Hou XL,. Effect of high dose of atorvastatin on contrast induced nephropathy in patients undergoing percutaneous coronary intervention. Mod J Integr Tradit Chin Western Med. 2012; 21 (28): 3113-3115.
21. He GX, Tan W,. Effect of high dose atorvastatin combined with hydration for prevention of contrast induced nephropathy in older patients undergoing emergency emergent percutaneous coronary intervention. J Guangxi Med Univ. 2012; 29 (4): 583-585.
22. Chen XY, Zhou LL,. Clinical study of preloading with atorvastatin on high doses of contrast media induced nephropathy. Chin J Clin Pharmacol Therap. 2013; 18 (6): 688-691.
23. Zhao Q, Xue F, Xu YJ, et al. Short-term high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention. Chin J Clin. 2013; 7 (3): 951-955.
24. Huang YL, Wang ZJ, Zhang WW, Li SX, Zhao LN, Yu HY,. Study of different dose atorvastatin in prevention of contrast induced nephropathy. Chin J Coal Ind Med. 2013; 16 (10): 1600-1602.
25. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151 (4): 264-269, W264.
26. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17 (1): 1-12.
27. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
28. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50 (4): 1088-1101.
29. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315 (7109): 629-634.
30. Zhang BC, Li WM, Xu YW,. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011; 27 (6): 851-858.
31. Meinel FG, De Cecco CN, Schoepf UJ, Katzberg R,. Contrast-induced acute kidney injury: definition, epidemiology, and outcome. Biomed Res Int. 2014; 2014: 859328.
32. Toso A, Leoncini M, Maioli M, et al. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. J Cardiovasc Med (Hagerstown). 2011; 12 (5): 318-321.
33. Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011; 57 (17): 1752-1761.
34. Guitterez NV, Diaz A, Timmis GC, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol. 2002; 15 (5): 349-354.
35. Ahlstrom A, Tallgren M, Peltonen S, Pettila V,. Evolution and predictive power of serum cystatin C in acute renal failure. Clin Nephrol. 2004; 62 (5): 344-350.
36. Solomon R, Dauerman HL,. Contrast-induced acute kidney injury. Circulation. 2010; 122 (23): 2451-2455.
37. Su JZ, Xue Y, Cai WQ, et al. Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin. Zhonghua Xin Xue Guan Bing Za Zhi. 2011; 39 (9): 807-811.
38. Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012; 126 (25): 3008-3016.
39. Su J, Zou W, Cai W, et al. Atorvastatin ameliorates contrast medium-induced renal tubular cell apoptosis in diabetic rats via suppression of rho-kinase pathway. Eur J Pharmacol. 2014; 723: 15-22.
40. Patti G,. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. J Cardiovasc Med (Hagerstown). 2011; 12 (5): 305-308.
41. Jang Y, Zhu J, Ge J, Kim YJ, Ji C, Lam W,. Preloading with atorvastatin before percutaneous coronary intervention in statin-naive Asian patients with non-ST elevation acute coronary syndromes: a randomized study. J Cardiol. 2013; 63 (5): 335-343.
42. Briguori C, Airoldi F, D'Andrea D, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007; 115 (10): 1211-1217.